Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
33.99
+0.12 (0.35%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,043,023
Profits / Employee
$134,481
Market Cap
3.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| ACADIA Pharmaceuticals | 798 |
| ADMA Biologics | 685 |
| Crinetics Pharmaceuticals | 594 |
| Xenon Pharmaceuticals | 370 |
| Alumis | 223 |
| Structure Therapeutics | 220 |
| Centessa Pharmaceuticals | 114 |
CORT News
- 6 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT - PRNewsWire
- 13 days ago - Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update - Business Wire
- 17 days ago - Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not - Seeking Alpha
- 18 days ago - Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals - Business Wire
- 18 days ago - Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Benzinga
- 20 days ago - Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 4 weeks ago - CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire